Publications
Mark G. Jones, Christopher R.T. Hillyar, Anjan Nibber, Alison Chisholm, Andrew Wilson, Toby M. Maher, Alan Kaplan, David Price, Simon Walsh, Luca Richeldi on behalf of the Respiratory Effectiveness Group’s Interstitial Lung Disease Working Group. Opportunities to diagnose fibrotic lung diseases in routine care: a primary care cohort study. Respirology 2020; Epub ahead of print.
[PubMed] [Full Text]
Marjan Kerkhof, Jaco Voorham, Paul Dorinsky, Claudia Cabrera, Patrick Darken, Janwillem WH Kocks, Mohsen Sadatsafavi, Don D Sin, David Price, Victoria Carter. Association between COPD exacerbations and lung function decline during maintenance therapy. Thorax 2020.
Konstantinos Kostikas, Chin Kook Rhee, John R. Hurst, Piergiuseppe Agostoni, Hui Cao, Robert Fogel, Rupert Jones, Janwillem W.H. Kocks, Karen Mezzi, Simon Wan Yau Ming, Ronan Ryan, David B. Price. Adequacy of therapy for people with both COPD and heart failure in the UK: historical cohort study. Pragmatic and Observational Research 2020.
David R Thickett, Jaco Voorham, Ronan Ryan, Rupert Jones, Robina Coker, Andrew Wilson, Sen Yang, Mandy Ow, Priyanka Raju, Isha Chaudhry, Antony Hardjojo, Victoria Carter, David Price. A historical database cohort study addressing the clinical patterns prior to idiopathic pulmonary fibrosis (IPF) diagnosis in UK primary care. BMJ Open 2020.
Marc Miravitlles, Pawel Sliwinski, Chin Kook Rhee, Richard W Costello, Victoria Carter, Jessica HY Tan, Therese S Lapperre, Bernardino Alcazar, Caroline Goulder, Cristina Esquinas, Juan Luis Garcia-Rivero, Anu Kemppinen, Augustus Tee, Miguel Roman-Rodriguez, Juan Jose Soler-Cataluna, David B Price. Predictive value of control of COPD for risk of exacerbations: An international, prospective study. Respirology 2020; Epub ahead of print.
[PubMed] [Full Text]
This international study used Quality Improvement enhanced OPCRD data as the UK source of data to investigate COPD control. A previous pilot study by OPRI using standard OPCRD data (Nibber et al.) aimed to test the concept of COPD control in the UK only and suggested potential clinical utility in predicting COPD outcomes. An international study by Miravitlles et al. then looked into the criteria for COPD control and found that they were too restrictive and were therefore not an accurate measure of disease prognosis.
This follow-up study then aimed to validate the concept of control of COPD in the long-term to use it as a predictor of the risk of exacerbations by using data from a range of countries across Europe and Asia. It defined controlled COPD as the patient achieving stable and low-impact disease after adjustment for disease severity as determined by FEV1. It found that determining COPD control with the use of clinical factors, such as the number of exacerbations in the previous three months, sputum presence and colour, breathlessness, etc, had more predictive value than when CAT scores were used. COPD control, as measured by these clinical factors that are easy to obtain during routine GP visits, was found to be predictive of both future exacerbations and time to next exacerbation.
Bright I Nwaru, Rebecca Pillinger, Holly Tibble, Syed A. Shah, Dermot Ryan, Hilary Critchley, David Price, Catherine M Hawrlylowicz, Colin R Simpson, Ireneous N Soyiri, Francis Appiagyei, Aziz Sheikh. Hormonal contraceptives and onset of asthma in reproductive-age women: population-based cohort study. J Allergy Clin Immunol 2020; Article in press.
[Full Text]
Hormonal fluctuations are known to contribute towards asthma outcomes in women. This study therefore investigated the relationship between the use of hormonal contraceptives and the risk of developing new-onset asthma in reproductive age women to better understand its influence over asthma outcomes. Found that women who used hormonal contraceptives had a reduced risk of developing asthma regardless of subtype of contraceptive, and a more reduced risk was identified in those who had been taking hormonal contraceptives for a longer period of time.
Vervloet M, van Dijk L, Spreeuwenberg P, Price D, Chisholm A, Van Ganse E, Pinnock H, Rand CS, Eakin MN, Schermer T, Souverein PC, Dima AL; Respiratory Effectiveness Group’s Adherence Working Group. The Relationship Between Real-World Inhaled Corticosteroid Adherence and Asthma Outcomes: A Multilevel Approach. J Allergy Clin Immunol Pract 2020;pii: S2213-2198(19)30780-9.
[PubMed] [Full Text]
Explored the relationship between adherence to inhaled corticosteroid (ICS) treatment and asthma control. Found that patients adapt the use of ICS to meet their current needs in a manner that does not greatly affect asthma control. Highlights the need to explore factors other than ICS implementation to improve asthma outcomes.
Krishnan JA, Nibber A, Chisholm A, Price D, Bateman ED, Bjermer L, van Boven JFM, Brusselle G, Costello RW, Dandurand RJ, Diamant Z, Van Ganse E, Gouder C, van Kampen SC, Kaplan A, Kocks J, Miravitlles M, Niimi A, Pizzichini E, Rhee CK, Soriano JB, Vogelmeier C, Román-Rodriguez M, Carter V, D’Urzo AD, Roche N. Prevalence and Characteristics of Asthma-Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices. Ann Am Thorac Soc 2019;16(9):1143-1150.
[PubMed] [Full Text]
Aimed to understand the prevalence and characteristics of asthma-COPD overlap (ACO) in three patient populations: those with asthma, those with COPD and those with both. Found that one in five patients had ACO and that most were male, in their 60s, former smokers, overweight or obese, and had several comorbidities. Demographics and comorbidities varied across the three populations.
David B. Price, Jaco Voorham, Guy Brusselle, Andreas Clemens, Konstantinos Kostikas, Jeffrey W. Stephens, Hye Yun Park, Nicolas Roche, Robert Fogel. Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study. npj Primary Care Respiratory Medicine. 2019;29(1):38.
[PubMed] [Full Text]
Found a link between ICS use and the onset of diabetes for COPD patients. Also observed a dose-response relationship between ICS use and the onset and worsening of diabetes, as well as the onset of osteoporosis.
Naomi Launders, Dermot Ryan, Christopher C Winchester, Derek Skinner, Priyanka Raju Konduru, David B Price. Management of community-acquired pneumonia: an observational study in UK primary care. Pragmatic and Observational Research. 2019;10.
[PubMed] [Full Text]
Highlighted the fact that despite the CRB65 scoring system being useful and accurate in determining when a hospital referral is required for community-acquired pneumonia, it is rarely utilized in primary care.
Kim KY, Miravitlles M, Sliwinski P, Costello R, Carter V, Tan J, Lapperre TS, Alcazar B, Gouder C, Esquinas C, García-Rivero JL, Kemppinen A, Tee A, Roman-Rodríguez M, Soler-Cataluña JJ, Price D, Rhee CK. Comparison of clinical baseline characteristics between Asian and Western COPD patients in a prospective, international, multicenter study. Int J Chron Obstruct Pulmon Dis 2019;14:1595-1601.
[PubMed] [Full Text]
Aimed to better characterize the phenotypes of COPD in two ethnic groups: Asian and Western. Found that Asian COPD patients were predominantly male, had a lower BMI, and lower exacerbation history compared to Western patients. Provides a foundation for future research to explore how these differences affect treatment outcomes.
Price DB, Bosnic-Anticevich S, Pavord ID, Roche N, Halpin DMG, Bjermer L, Usmani OS, Brusselle G, Ming SWY, Rastogi S. Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. Clin Transl Allergy 2019;9(41).
[PubMed] [Full Text]
Fractional exhaled nitric oxide (FeNO) concentration and blood eosinophil count (BEC) are established biomarkers of asthma. This study found that when both are elevated, there is a high risk of severe asthma exacerbations; they can therefore be combined to identify at-risk patients.
Halpin DMG, Dejong HJI, Carter V, Skinner D, Price D. Distribution, temporal stability and appropriateness of therapy of patients with COPD in the UK in relation to GOLD 2019. EClinicalMedicine 2019;14:32-41.
[Full Text]
Analyzed the distribution of COPD patients by GOLD group criteria over a two-year period. Also looked at treatment patterns and comorbidities. Found substantial movement of the patients between GOLD groups over the two years and highlighted the fact that prescribing patterns were often not in line with guideline recommendations; patients were often overtreated, especially those of lower risk.
Jaco Voorham, Massimo Corradi, Alberto Papi, Claus F. Vogelmeier, Dave Singh, Leonardo M. Fabbri, Marjan Kerkhof, Janwillem H. Kocks, Victoria Carter, David Price. Comparative effectiveness of triple therapy versus dual bronchodilation in COPD. ERJ Open Res 2019;5(3).
[PubMed] [Full Text]
Evaluated the real-world effectiveness of triple therapy, as compared to dual bronchodilation, in a COPD population experiencing frequent exacerbations. Found triple therapy to be more effective in reducing exacerbation risk.
Simon Wan Yau Ming, John Haughney, Dermot Ryan, Shishir Pate, Matthias Oche, Martina Stagno d’Alcontres, Susannah Thornhill, Janwillem WH Kocks, David Price. Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma. NPJ Prim Care Respir Med 2019; 29(1):3.
[PubMed] [Full Text]
Compared ICS-related adverse events between the addition of an unlicensed spacer (Aerochamber®) and a licenced one (Volumatic®) to an inhaler. Found no significant difference between the two in terms of patient-reported or EMR-recorded ICS-related adverse events.
Marc Miravitlles, Pawel Sliwinski, Chin Kook Rhee, Richard W Costello, Victoria Carter, Jessica Tan, Therese Sophie Lapperre, Bernardino Alcazar, Caroline Goulder, Cristina Esquinas, Juan Luis Garcia-Rivero, Anu Kemppinen, Augustine Tee, Miguel Roman-Rodriguez, Juan Jose Soler-Cataluna, David Price. Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD. Resp Med 2018;136:8-14.
Luke E Barry, Ciaran O’Neill, Chris Patterson, Joan Sweeney, David Price, Liam G Heaney. Age and Sex Associations with Systemic Corticosteroid-Induced Morbidity in Asthma. J Aller Clin Immunol: In Pract 2018;6(6):2014-2023.e2
Bright I Nwaru, Colin R Simpson, Ireneous N Soyiri, Rebecca Pillinger, Francies Appiagyei, Dermot Ryan, Hilary Critchley, David B Price, Catherine M Hawrylowicz, Aziz Sheikh. Exogenous sex steroid hormones and asthma in females: protocol for a population-based retrospective cohort study using a UK primary care database. BMJ Open 2018;8(6):020075.
David B. Price, Eran Gefen, Gokul Gopalan, Rosie McDonald, Vicky Thomas, Simon Wan Yau Ming, Emily Davis. Real-life effectiveness and safety of Salbutamol Steri-neb™ vs. Ventolin Nebules® in preventing exacerbations in patients with COPD: historical cohort study. PLoS One 2018; 13(1): e0191404.
[PubMed] [Full Text]
Alberto Papi, Dermot Ryan, Joan B. Soriano, Henry Chrystyn, Leif Bjermer, Roberto Rodríguez-Roisin, Myrna B. Dolovich, Mark Harris, Lucy Wood, Maria Batsiou, Susannah I. Thornhill, David B. Price. Relationship of inhaled corticosteroid adherence to asthma exacerbations in patients with moderate-to-severe asthma. J Allergy Clin Immunol Pract 2018.
[PubMed] [Full Text]
Joan B Soriano, Sarah Lucas, Rupert Jones, Marc Miravitlles, Victoria Carter, Iain Small, David Price, Ravi Mahadeva. Trends of testing for and diagnosis of alpha-1 antitrypsin deficiency in the UK: more testing is needed. Eur Respir J 2018; 52(1): 1800360.
[PubMed] [Full Text]
Steve W Turner, Clare Murray, Mike Thomas, Annie Burden & David B Price. Applying UK real-world primary care data to predict asthma attacks in 3776 well-characterised children: a retrospective cohort study. npj Prim Care Respir Med 2018; 28(1): 28.
[PubMed] [Full Text]
Gene Colice, Alison Chisholm, Alexandra L Dima, Helen K Reddel, Annie Burden, Richard J Martin, Guy Brusselle, Todor A Popov, Julie von Ziegenweidt, David B Price. Performance of database-derived severe exacerbations and asthma control measures in asthma: responsiveness and predictive utility in a UK primary care database with linked questionnaire data. Pragmat Obs Res 2018; 9: 29-42.
[PubMed] [Full Text]
Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, Tran TN. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy 2018;11:193-204.
[PubMed] [Full Text]
Jaco Voorham, Nicolas Roche, Hicham Benhaddi, Marianka van der Tol, Victoria Carter, Job F.M. van Boven, Leif Bjermer, Marc Miravitlles, David B Price. Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK. BMJ Open 2018; 8(10): e022051.
[PubMed] [Full Text]
Jonathan Grigg, Anjan Nibber, James Y. Paton, Alison Chisholm, Theresa W. Guilbert, Alan Kaplan, Steve Turner, Nicolas Roche, Elizabeth V. Hillyer, David B. Price, Respiratory Effectiveness Group. Matched cohort study of therapeutic strategies to prevent preschool wheezing/asthma attacks. The Journal of Asthma and Allergy 2018; 11: 309—321.
[PubMed] [Full Text]
Sinthia Bosnic-Anticevich, Vicky Kritikos, Victoria Carter, Kwok Yin Yan, Carol Armour, Dermot Ryan, David Price. Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed dose combination therapy in Australia. Journal of Asthma 2018;55(6):684-694.
[PubMed] [Full Text]
Sinthia Bosnic-Anticevich, Christina Callan, Henry Chrystyn, Federico Lavorini, Vasilis Nikolaou, Vicky Kritikos, PN Richard Dekhuijzen, Nicolas Roche, Leif Bjermer, Cynthia Rand, Nicholas Zwar, David B Price. Inhaler technique mastery and maintenance in healthcare professionals trained on different devices. J Asthma 2018: 55(1): 79-88.
[PubMed] [Full Text]
Patrick C Souverein, Ellen S Koster, Gene Colice, Eric van Ganse, Alison Chisholm, David Price, Alexandra L Dima, Respiratory Effectiveness Group’s Adherence Working Group. Inhaled Corticosteroid Adherence Patterns in a Longitudinal Asthma Cohort. J Aller Clin Immunol: In Pract 2017; 5(2):448-456.e2
Luke E Barry, Joan Sweeney, Ciaran O’Neill, Liam G Heaney. The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis. Resp Research 2017;18:129.
Anjan Nibber, Alison Chisholm, Juan Jose Soler-Cataluna, Bernardino Alcazar, David Price, Marc Miravitlles. Validating the Concept of COPD Control: A Real-world Cohort Study from the United Kingdom. COPD: J of COPD 2017;14(5):504-512.
Marjan Kerkhof, Trung N Tran, Joan B Soriano, Sarowar Golam, Danny Gibson, Elizabeth V Hillyer, David B Price. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax 2017;73:116-124.
Thys van der Molen, Monica Fletcher, and David Price. Identifying patient attitudinal clusters associated with asthma control: the European REALISE survey. J Allergy Clin Immunol Pract 2017;6(3):962-971.
[PubMed] [Full Text]
A Simon Carney, David B Price, Pete K Smith, Richard Harvey, Vicky Kritikos, Sinthia Z Bosnic-Anticevich, Louise Christian, Derek A Skinner, Victoria Carter, Alice MS Durieux. Seasonal patterns of oral antihistamine and intranasal corticosteroid purchases from Australian community pharmacies: a retrospective observational study. Pragmat Obs Res 2017;8:157-165.
[PubMed] [Full Text]
Rupert Jones, Jessica Martin, Vicky Thomas, Derek Skinner, Jonathan Marshall, Martina Stagno d’Alcontres, David Price. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study. Int J Chron Obstruct Pulmon Dis 2017;12:2445-2454.
[PubMed] [Full Text]
Simon Wan Yau Ming, John Haughney, Iain Small, Stephanie Wolfe, John Hamill, Kevin Gruffydd-Jones, Cathal Daly, Joan B. Soriano, Elizabeth Gardener, Derek Skinner, Martina Stagno d’Alcontres, David B. Price. Initiating or changing to a fixed-dose combination of fluticasone propionate/formoterol over fluticasone propionate/salmeterol: a real-life effectiveness and cost impact evaluation. Respir Med 2017;129:199-206.
[PubMed] [Full Text]
Samatha Sonnappa, Richard J. Martin, Elliot Israel, Dirkje Postma, Wim van Aalderen, Anne Burden, David B Price, Omar S. Usmani. Risk of pneumonia in obstructive lung disease: a real-life study comparing extra-fine and fine-particle inhaled corticosteroids. PLoS One 2017;12(6):e0178112.
[PubMed] [Full Text]
Kevin Gruffydd-Jones, Guy Brusselle, Rupert Jones, Marc Miravitlles, Michael Baldwin, Rebecca Stewart, Anna Rigazio, Emily Davis, Dorothy L Keininger & David Price. Erratum: Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: a real-world study. NPJ Prim Care Respir Med 2017;27:17004.
[PubMed] [Full Text]
Dirkje S. Postma, Alan Kaplan, Joan B. Soriano, Jonathon Grigg, Theresa W. Guilbert, Wim van Aalderen, Nicolas Roche, Anne Burden, Elizabeth V. Hillyer, Elliot Israel, David B. Price. Cohort analysis of exacerbation rates in adolescent and adult patients initiating inhaled corticosteroids for asthma: different dose-response profile by particle size. Pulm Ther 2017;3(1):113-124.
[Full Text]
Jaco Voorham, Bernard Vrijens, Job FM van Boven, Dermot Ryan, Marc Miravitlles, Lisa M Law, David B Price. Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study. Pragmat Obs Res 2017;8:31-41.
[PubMed] [Full Text]
Omar S. Usmani, Anu Kemppinen, Elizabeth Gardener, Vicky Thomas, Priyanka Raju Konduru, Christina Callan, Andrew McLoughlin, Vanessa Woodhead, Adam Brady, Elizabeth F Juniper, Peter J Barnes, David B. Price. A randomized pragmatic trial of changing to and stepping down fluticasone/formoterol in asthma. J Allergy Clin Immunol Pract 2017;5(5):1378-1387.e5.
[PubMed] [Full Text]
David B. Price, Miguel Román-Rodríguez, R. Brett McQueen, Sinthia Bosnic-Anticevich, Victoria Carter, Kevin Gruffydd-Jones, John Haughney, Svein Henrichsen, Catherine Hutton, Antonio Infantino, Federico Lavorini, Lisa M. Law, Karin Lisspers, Alberto Papi, Dermot Ryan, Björn Ställberg, Thys van der Molen, Henry Chrystyn. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract 2017;5(4):1071-81.e9.
[PubMed] [Full Text]
Clare S. Murray, Mike Thomas, Kathryn Richardson, David B. Price, Steve W. Turner. Comparative effectiveness of step-up therapies in children with asthma prescribed inhaled corticosteroids: a historical cohort study. J Allergy Clin Immunol Pract 2017; 5(4): 1082-1090.e7.
[PubMed] [Full Text]
Theresa W. Guilbert, Gene Colice, Jonathan Grigg, Wim van Aalderen, Richard J. Martin, Elliot Israel, Dirkje S. Postma, Nicolas Roche, Wanda Phipatanakul, Elizabeth V. Hillyer, Jennifer M. Evans, Myrna B. Dolovich, David B. Price; in collaboration with the Respiratory Effectiveness Group. Real-life outcomes for patients with asthma prescribed spacers for use with either extrafine- or fine-particle inhaled corticosteroids. J Allergy Clin Immunol Pract 2017;5(4):1040-1049.e4.
[PubMed] [Full Text]
Sinthia Bosnic-Anticevich, Henry Chrystyn, Richard W Costello, Myrna B Dolovich, Monica J Fletcher, Federico Lavorini, Roberto Rodríguez-Roisin, Dermot Ryan, Simon Wan Yau Ming, David B Price. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis 2017;12:59-71.[PubMed] [Full Text]
Steve Turner, Kathryn Richardson, Clare Murray, Mike Thomas, Elizabeth V. Hillyer, Anne Burden, David B. Price; on behalf of the Respiratory Effectiveness Group. Long-acting β-agonist in combination or separate inhaler as step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. J Allergy Clin Immunol Pract 2017;5(1):99–106.e3.
[PubMed] [Full Text]
Samatha Sonnappa, Brett McQueen, Dirkje S. Postma, Richard J. Martin, Nicolas Roche, Jonathan Grigg, Theresa Guilbert, Caroline Gouder, Emilio Pizzichini, Akio Niimi, Wanda Phipatanakul, Alison Chisholm, Ronald J. Dandurand, Alan Kaplan, Elliot Israel, Alberto Papi, Willem M.C. van Aalderen, Omar S. Usmani, David B. Price. Extrafine versus fine inhaled corticosteroids in relation to asthma control: a systematic review and meta-analysis of observational real-life studies. J Allergy Clin Immunol Pract 2017;6(3):907-915.e7.
Marjan Kerkhof, Elizabeth V. Hillyer, David B. Price. Reply [The effect of smoking on exacerbation risk in eosinophilic patients with chronic obstructive pulmonary disease]. Eur Respir J 2017;50:1702086.
[PubMed] [Full Text]
Marjan Kerkhof, Samatha Sonnappa, Dirkje S. Postma, Guy Brusselle, Alvar Agustí, Antonio Anzueto, Rupert Jones, Alberto Papi, Ian Pavord, Emilio Pizzichini, Todor Popov, Nicolas Roche, Dermot Ryan, Mike Thomas, Claus Vogelmeier, Alison Chisholm, Daryl Freeman, Mona Bafadhel, Elizabeth V. Hillyer and David B. Price. Blood eosinophil count and exacerbation risk in patients with COPD. Eur Respir J 2017;50(1):1700761.
[PubMed] [Full Text]
Joan Sweeney, Chris C Patterson, Andrew Menzies-Gow, Rob M Niven, Adel H Mansur, Christine Bucknall, Rekha Chaudhuri, David Price, Chris E Brightling, Liam G Heaney, on behalf of the British Thoracic Society Difficult Asthma Network. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. BMJ Open;71(4):399-346.
Rupert C Jones, David Price, Niels H Chavannes, Amanda J Lee, Michael E Hyland, Bjorn Stallberg, Karin Lisspers, Josefin Sundh, Thys van der Molen, Ioanna Tsiligianni. Multi-component assessment of chronic obstructive pulmonary disease: an evaluation of the ADO and DOSE indices and the global obstructive lung disease categories in international primary care data sets. npj Prim Care Resp Med 2016;26:16010.
Kevin Gruffyd-Jones, Guy Brusselle, Rupert Jones, Marc Miravitlles, Michael Baldwin, Rebecca Stewart, Anna Rigazio, Emily Davis, Dorothy L Keininger, David Price. Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: a real-world, retrospective, observational study. npj Prim Care Resp Med 2016;26:16002.
John D Blakey, David B Price, Emilio Pizzichini, Todor A Popov, Borislav D Dimitrov, Dirkje S. Postma, Lynn K. Josephs, Alan Kaplan, Alberto Papi, Marjan Kerkhof, Elizabeth V Hillyer, Alison Chisholm, Mike Thomas. Identifying risk of future asthma attacks using UK medical record data: a Respiratory Effectiveness Group initiative. J Allergy Clin Immunol 2016; 5(4): 1015-1024.e8.
[PubMed] [Full Text]
P.N. Richard Dekhuijzen, Maria Batsiou, Leif Bjermer, Sinthia Bosnic-Anticevich, Henry Chrystyn, Alberto Papi, Roberto Rodríguez-Roisin, Monica Fletcher, Lucy Wood, Alessandra Cifra, Joan B. Soriano, David B. Price. Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device. Respir Med 2016; 120: 54-63.
[PubMed] [Full Text]
David M. G. Halpin, Marjan Kerkhof, Joan B. Soriano, Helga Mikkelsen, David B. Price. Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respir Res 2016; 17(1): 120.
[PubMed] [Full Text]
David B. Price, Richard Russell, Rafael Mares, Anne Burden, Derek Skinner, Helga Mikkelsen, Cherlyn Ding, Richard Brice, Niels H. Chavannes, Janwillem W. H. Kocks, Jeffrey W. Stephens, John Haughney. Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study. PLoS One 2016; 11(9): e0162903.
[PubMed] [Full Text]
Manon Belhassen, Anjan Nibber, Eric Van Ganse, Dermot Ryan, Carole Langlois, Francis Appiagyei, Derek Skinner, Laurent Laforest, Joan B Soriano,David Price. Inappropriate asthma therapy — a tale of two countries: a parallel population-based cohort study. NPJ Prim Care Respir Med 2016; 26: 16076.
[PubMed] [Full Text]
David B Price, Anna Rigazio, Mary Buatti Small, Thomas J Ferro. Historical cohort study examining comparative effectiveness of albuterol inhalers with and without integrated dose counter for patients with asthma or chronic obstructive pulmonary disease. J Asthma Allergy 2016; 9: 145-54.
[PubMed] [Full Text]
David Price, Marc Miravitlles, Ian Pavord, Mike Thomas, Jadwiga Wedzicha, John Haughney, Katsiaryna Bichel, Daniel West. First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis. NPJ Prim Care Respir Med 2016; 26: 16061.
[PubMed] [Full Text]
Brian Lipworth, Derek Skinner, Graham Devereux, Victoria Thomas, Joanna Ling Zhi Jie, Jessica Martin, Victoria Carter, David B Price. Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease. Heart 2016; 102(23): 1909-14.
[PubMed] [Full Text]
David B Price, Glenis Scadding, Claus Bachert, Hesham Saleh, Shuaib Nasser, Victoria Carter, Julie von Ziegenweidt, Alice MS Durieux, Dermot Ryan. UK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational study. NPJ Prim Care Respir Med 2016; 26:16033.
[PubMed] [Full Text]
David B. Price, Gene Colice, Elliot Israel, Nicolas Roche, Dirkje S. Postma, Theresa W. Guilbert, Willem M.C. van Aalderen, Jonathan Grigg, Elizabeth V. Hillyer, Vicky Thomas, Richard J. Martin. Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler. ERJ Open Res 2016; 2(2).
[Full Text]
Nicolas Roche, Gene Colice, Elliot Israel, Richard J. Martin, Paul M. Dorinsky, Dirkje S. Postma, Theresa W. Guilbert, Jonathan Grigg, Willem M. C. van Aalderen, Francesca Barion, Elizabeth V. Hillyer, Victoria Thomas, Anne Burden, R. Brett McQueen, David B. Price. Cost-effectiveness of asthma step-up therapy as an increased dose of extrafine-particle inhaled corticosteroid or add-on long-acting beta2-agonist. Pulm Ther 2016; 2: 73-89.
[Full Text]
Kevin Gruffydd-Jones, Guy Brusselle, Rupert Jones, Marc Miravitlles, Michael Baldwin, Rebecca Stewart, Anna Rigazio, Emily Davis, Dorothy L Keininger, David Price. Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: in UK primary care: a real-world, retrospective, observational. NPJ Prim Care Respir Med 2016; 26: 16002.
[Full Text]
David Price, Andrew M Wilson, Alison Chisholm, Anna Rigazio, Anne Burden, Michael Thomas, Christine King. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy 2016; 9: 1-12.
[PubMed] [Full Text]
David Price, Brooke Harrow, Mark Small, James Pike, Victoria Higgins. Establishing the relationship of inhaler satisfaction, treatment adherence, and patient outcomes: a prospective, real-world, cross-sectional survey of US adult asthma patients and physicians. World Allergy Organ J 2015;8(1):26
[PubMed] [Full Text]
Marjan Kerkhof, Daryl Freeman, Rupert Jones, Alison Chisholm, David B Price; on behalf of the Respiratory Effectiveness Group. Predicting frequent COPD exacerbations using primary care data. Int J Chron Obstruct Pulmon Dis 2015; 10: 2439-50.
[PubMed] [Full Text]
David B Price, Anna Rigazio, Jonathan D Campbell, Eugene R Bleecker, Christopher J Corrigan, Mike Thomas, Sally E Wenzel, Andrew M Wilson, Mary Buatti Small, Gokul Gopalan, Valerie L Ashton, Anne Burden, Elizabeth V Hillyer, Marjan Kerkhof, Ian D Pavord. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015; 3(11): 849–58.
[PubMed] [Full Text]
Willem M.C. van Aalderen, Jonathan Grigg, Theresa W. Guilbert, Nicolas Roche, Elliot Israel, Richard J. Martin, Gene Colice, Dirkje S. Postma, Elizabeth V. Hillyer, Anne Burden, Victoria Thomas, Julie von Ziegenweidti, David Price. Small-particle inhaled corticosteroid as first-line or step-up controller therapy in childhood asthma. J Allergy Clin Immunol Pract 2015; 3(5): 721-31.e16.
[PubMed] [Full Text]
Steve W Turner, Kathryn Richardson, Annie Burden, Mike Thomas, Clare Murray, David Price. Initial step-up treatment changes in asthmatic children already prescribed inhaled corticosteroids: a historical cohort study. NPJ Prim Care Respir Med 2015; 25: 15041.
[PubMed] [Full Text]
Elliot Israel, Nicolas Roche, Richard J. Martin, Gene Colice, Paul M. Dorinsky, Dirkje S. Postma, Theresa W. Guilbert, Willem M. C. van Aalderen, Jonathan Grigg, Elizabeth V. Hillyer, Anne Burden, Julie von Ziegenweidt, Victoria Thomas, David B. Price. Increased dose of inhaled corticosteroid versus add-on long-acting β-agonist for step-up therapy in asthma. Ann Am Thorac Soc 2015; 12(6): 798-806.
[PubMed] [Full Text]
David Price, Alan Kaplan, Rupert Jones, Daryl Freeman, Anne Burden, Shuna Gould, Julie von Ziegenweidt, Muzammil Ali, Christine King, Mike Thomas. Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide. J Asthma Allergy 2015; 8: 1-13.
[PubMed] [Full Text]
Nicolas Roche, Dirkje S. Postma, Gene Colice, Anne Burden, Theresa W. Guilbert, Elliot Israel, Richard J. Martin, Willem M. C. van Aalderen, Jonathan Grigg, Elizabeth V. Hillyer, Julie von Ziegenweidt, David B. Price. Differential effects of inhaled corticosteroids in smokers/ex-smokers and nonsmokers with asthma. Am J Respir Crit Care Med 2015; 191(8): 960-4.
[PubMed] [Full Text]
Richard J Martin, David Price, Nicolas Roche, Elliot Israel, Willem MC van Aalderen, Jonathan Grigg, Dirkje S Postma, Theresa W Guilbert, Elizabeth V Hillyer, Anne Burden, Julie von Ziegenweidt, Gene Colice. Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study. NPJ Prim Care Respir Med 2014; 24: 14081.
[PubMed] [Full Text]
Dirkje S Postma, Nicolas Roche, Gene Colice, Elliot Israel, Richard J Martin, Willem MC van Aalderen, Jonathan Grigg, Anne Burden, Elizabeth V Hillyer, Julie von Ziegenweidt, Gokul Gopalan, David Price. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int J Chron Obstruct Pulmon Dis 2014; 9: 1163-86.
[PubMed] [Full Text]
David Price, Daniel West, Guy Brusselle, Kevin Gruffydd-Jones, Rupert Jones, Marc Miravitlles, Andrea Rossi, Catherine Hutton, Valerie L Ashton, Rebecca Stewart, Katsiaryna Bichel. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis 2014; 9: 889-904.
[PubMed] [Full Text]
David Price, Vicky Thomas, Julie von Ziegenweidt, Shuna Gould, Catherine Hutton, Christine King. Switching patients from other inhaled corticosteroid devices to the Easyhaler®: historical, matched-cohort study of real-life asthma patients. J Asthma Allergy 2014; 10(7): 31-51.
[PubMed] [Full Text]
Rupert C M Jones, David Price, Dermot Ryan, Erika J Sims, Julie von Ziegenweidt, Laurence Mascarenhas, Anne Burden, David M G Halpin, Robert Winter, Sue Hill, Matt Kearney, Kevin Holton, Anne Moger, Daryl Freeman, Alison Chisholm, Eric D Bateman, on behalf of The Respiratory Effectiveness Group. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med 2014; 2(4): 267-76.
[PubMed] [Full Text]
David Price, Yumi Asukai, Jaithri Ananthapavan, Bill Malcolm, Amr Radwan, Ian Keyzor. A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use. Applied Health Economics and Health Policy 2013;11:259-274.
David Price, Mike Thomas, John Haughney, Richard A Lewis, Anne Burden, Julie von Ziegenweidt, Alison Chisholm, Elizabeth V. Hillyer, Christopher J. Corrigan. Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma. Respir Med 2013;107(7):987-1000.
David Price, Dermot Ryan, Annie Burden, Julie Von Ziegenweidt, Shuna Gould, Daryl Freeman, Kevin Gruffydd-Jones, Anne Copland, Clifford Godley, Alison Chisholm, Mike Thomas. Using fractional exhaled nitric oxide (FeNO) to diagnose steroid-responsive disease and guide asthma management in routine care. Clin Transl Allergy 2013; 3(1): 37.
[PubMed] [Full Text]
David Price, Iain Small, John Haughney, Dermot Ryan, Kevin Gruffydd-Jones, Federico Lavorini, Tim Harris, Annie Burden, Jeremy Brockman, Christine King, Alberto Papi. Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. Prim Care Respir J 2013; 22(4): 439-48.
[PubMed] [Full Text]
David Price, Mike Thomas, John Haughney, Richard A. Lewis, Anne Burden, Julie von Ziegenweidt, Alison Chisholm, Elizabeth V. Hillyer, Christopher J. Corrigan. Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma. Respir Med 2013; 107(7): 987-1000.
[PubMed] [Full Text]
David Price, Amanda J Lee, Erika J Sims, Linda Kemp, Elizabeth V Hillyer, Alison Chisholm, Julie von Ziegenweidt, Angela Williams. Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study. Prim Care Respir J 2013; 22(2): 161-8.
[PubMed] [Full Text]
David Price, Alison Chisholm, Elizabeth V Hillyer, Annie Burden, Julie von Ziegenweidt, Henrik Svedsater, Peter Dale. Effect of inhaled corticosteroid therapy step-down and dosing regimen on measures of asthma control. J Allergy Ther 2013; 4(1): 126.
David Price, Leif Bjermer, John Haughney, Nicolas Roche, Jean Bousquet, Elizabeth V. Hillyer, Alison Chisholm. Real-life asthma strategies: the missing piece in the jigsaw. Treatment Strategies – Respiratory 2013; 3(2): 37-46.
Publications
Number of publications throughout the years.
Optimum Patient Care Research Database is proud to have supported more than 80 research publications in disease management, therapy and science.